QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NASDAQ:EUCR

Eucrates Biomedical Acquisition Stock Forecast, Price & News

$10.12
+0.10 (+1.00 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.10
Now: $10.12
$10.12
50-Day Range
$10.02
MA: $10.39
$10.64
52-Week Range
$9.76
Now: $10.12
$10.88
Volume1,200 shs
Average Volume29,518 shs
Market Capitalization$136.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eucrates Biomedical Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Industry Shell Companies
Sub-IndustryN/A
Current SymbolNASDAQ:EUCR
CUSIPN/A
CIKN/A
WebN/A
Phone212-710-5220
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$136.21 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.00 out of 5 stars

Unclassified Sector

190th out of 246 stocks

Shell Companies Industry

202nd out of 281 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$10.12
+0.10 (+1.00 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EUCR News and Ratings via Email

Sign-up to receive the latest news and ratings for EUCR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Eucrates Biomedical Acquisition (NASDAQ:EUCR) Frequently Asked Questions

What stocks does MarketBeat like better than Eucrates Biomedical Acquisition?

Wall Street analysts have given Eucrates Biomedical Acquisition a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eucrates Biomedical Acquisition wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Eucrates Biomedical Acquisition's key executives?

Eucrates Biomedical Acquisition's management team includes the following people:
  • Mr. Parag Phoolchand Saxena MBA, MS, CEO & Director (Age 65)
  • Dr. Evangelos Vergetis, Pres, COO & Director (Age 42)
  • Mr. Gonzalo Cordova CFA, Chief Financial Officer (Age 66)
  • Mr. Shrikant Sathe, Sr. VP (Age 67)

Who are some of Eucrates Biomedical Acquisition's key competitors?

What is Eucrates Biomedical Acquisition's stock symbol?

Eucrates Biomedical Acquisition trades on the NASDAQ under the ticker symbol "EUCR."

Who are Eucrates Biomedical Acquisition's major shareholders?

Eucrates Biomedical Acquisition's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (2.97%), Granite Point Capital Management L.P. (2.84%) and Radcliffe Capital Management L.P. (0.74%).

Which institutional investors are buying Eucrates Biomedical Acquisition stock?

EUCR stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Granite Point Capital Management L.P., and Radcliffe Capital Management L.P..

How do I buy shares of Eucrates Biomedical Acquisition?

Shares of EUCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eucrates Biomedical Acquisition's stock price today?

One share of EUCR stock can currently be purchased for approximately $10.12.

How much money does Eucrates Biomedical Acquisition make?

Eucrates Biomedical Acquisition has a market capitalization of $136.21 million.

Where are Eucrates Biomedical Acquisition's headquarters?

Eucrates Biomedical Acquisition is headquartered at 250 WEST 55TH STREET SUITE 13D, NEW YORK NY, 10019.

How can I contact Eucrates Biomedical Acquisition?

Eucrates Biomedical Acquisition's mailing address is 250 WEST 55TH STREET SUITE 13D, NEW YORK NY, 10019. The company can be reached via phone at 212-710-5220.


This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.